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Abstract
Objectives We used the results of the Global Burden of
Disease 2015 study to estimate trends of HIV/AIDS burden
in Eastern Mediterranean Region (EMR) countries between
1990 and 2015.
Methods Tailored estimation methods were used to pro-
duce final estimates of mortality. Years of life lost (YLLs)
were calculated by multiplying the mortality rate by pop-
ulation by age-specific life expectancy. Years lived with
disability (YLDs) were computed as the prevalence of a
sequela multiplied by its disability weight.
Results In 2015, the rate of HIV/AIDS deaths in the EMR
was 1.8 (1.4–2.5) per 100,000 population, a 43% increase
from 1990 (0.3; 0.2–0.8). Consequently, the rate of YLLs
due to HIV/AIDS increased from 15.3 (7.6–36.2) per
100,000 in 1990 to 81.9 (65.3–114.4) in 2015. The rate of
YLDs increased from 1.3 (0.6–3.1) in 1990 to 4.4 (2.7–6.6)
in 2015.
Conclusions HIV/AIDS morbidity and mortality increased
in the EMR since 1990. To reverse this trend and achieve
epidemic control, EMR countries should strengthen HIV
surveillance, and scale up HIV antiretroviral therapy and
comprehensive prevention services.
Keywords HIV  HIV mortality  Eastern Mediterranean
Region  Burden of disease
Introduction
In 2015, HIV/AIDS was the 12th-leading cause of death
worldwide after being the eighth in 2005 when the epi-
demic peaked (Institute for Health Metrics and Evaluation
(IHME) 2017). More than 1.2 million people are estimated
to have died in 2015 due to HIV/AIDS despite the con-
siderable achievements in HIV care since the late 1980s
(Wang et al. 2016b). This reflects the challenges faced by
public health policymakers and program managers, health
professionals, and the global community in dealing with
this epidemic.
The burden of the HIV/AIDS epidemic has rapidly
changed since the 1990s with the introduction of HIV
antiretroviral therapy (ART) and other effective interven-
tions (UNAIDS 2015). While incidence has declined con-
tinuously since the mid-1990s, mortality continued to rise
and peaked in 2005 at 1.8 million deaths worldwide (Wang
et al. 2016b). Inspired by the successes of responding to
AIDS, global leaders have committed to and embarked on
ending the AIDS epidemic as a public health threat by
2030, without leaving anyone behind (UNAIDS 2014a).
Today, there are large variations in incidence and mortality
between regions and countries (Wang et al. 2016b). In the
Eastern Mediterranean Region (EMR), and despite recent
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progress (Institute for Health Metrics and Evaluation
(IHME) 2017), estimates of HIV/AIDS continue to be
challenged with limitations in data availability and by
insufficient epidemiological surveillance among those most
at-risk of infection (Shawky et al. 2009; Mumtaz et al.
2014a). The EMR has a population of about 583 million
people. Countries in the EMR vary significantly in terms of
their gross domestic product, socio-demographic profiles,
health indicators, and health system capacities and cover-
age (WHO EMRO 2017).
The EMR has several vulnerability factors for HIV (Abu-
Raddad et al. 2010). The socio-cultural and socioeconomic
fabric as well as the demographic structure of the region is
evolving rapidly (Abu-Raddad et al. 2010). Extensive levels
of migration, displacement, mobility, and conflicts are a
hallmark of the region (UNAIDS RST MENA 2008).
Injection drug use is also a major challenge in a region that
produces most of the world’s supply of heroin and is at the
crossroads of major drug trade routes (UNODC 2007).
The emerging HIV epidemics among the most at-risk
populations, such as men who have sex with men (MSM)
and people who inject drugs (PWID), constitute the main
feature of HIV epidemiology in the EMR today within a
context that criminalizes and marginalizes these popula-
tions (Simmons 2014; Mumtaz et al. 2014a). The majority
of these epidemics are recent, having emerged within the
last two decades (Mumtaz et al. 2014b). In addition to these
documented epidemics, there is evidence suggesting hid-
den, undetected epidemics among the most at-risk popu-
lations in countries with still weak HIV surveillance
systems (Mumtaz et al. 2014a).
Data on disability and mortality from HIV are crucial in
understanding the regional response to the disease. To
inform HIV policy, programming, and resource allocation
about the state of the epidemic in EMR countries, we used
the results of the GBD 2015 study to report the HIV/AIDS
burden in these countries.
Methods
The Eastern Mediterranean Region (EMR) countries, based
on the World Health Organization classification, are the
Islamic Republic of Afghanistan, the Kingdom of Bahrain,
Djibouti, the Arab Republic of Egypt, the Islamic Republic
of Iran, the Republic of Iraq, the Hashemite Kingdom of
Jordan, the State of Kuwait, Lebanon, the State of Libya,
the Kingdom of Morocco, the Sultanate of Oman, the
Islamic Republic of Pakistan, Palestine, the State of Qatar,
the Kingdom of Saudi Arabia, the Federal Republic of
Somalia, the Republic of Sudan, the Syrian Arab Republic,
the Republic of Tunisia, the United Arab Emirates, and the
Republic of Yemen.
A detailed methodology of HIV/AIDS mortality esti-
mation for GBD 2015 has been published elsewhere (Wang
et al. 2016b). We used all available data sources including
vital registration, verbal autopsies, surveys, publications,
and reports. These data sources have been published else-
where as an appendix (Wang et al. 2016b), and are avail-
able from the Global Health Data Exchange (Institute for
Health Metrics and Evaluation 2017). Briefly, the GBD
estimation framework contains three sources for estimates
of HIV-specific mortality: estimated HIV mortality from
Spectrum (Brown et al. 2014; Stover et al. 2014); estimated
excess HIV/AIDS mortality in our all-cause mortality
estimation process; and spatiotemporal Gaussian process
regression smoothed cause-specific HIV/AIDS mortality
from vital registration (VR) systems that were adjusted for
incompleteness and misclassification of causes of death
(Wang et al. 2016a). Tailored estimation methods were
used to produce final estimates of mortality depending on
age groups and the availability and quality of data for
mortality of HIV/AIDS.
Years of life lost (YLLs) were calculated by multiplying
the mortality rate by population by age-specific life
expectancy from the reference life table used in the GBD
study. Years lived with disability (YLDs) were computed
as the prevalence of a sequela multiplied by the disability
weight for that sequela without age weighting or dis-
counting. The YLDs arising from HIV/AIDS are the sum
of the YLDs for each of the sequelae associated with HIV/
AIDS. Disability-adjusted life years (DALYs) are com-
puted as the sum of YLLs and YLDs. Detailed methods on
YLLs, YLDs, and DALYs are published elsewhere (GBD
2015 DALYs and HALE Collaborators 2016; GBD 2015
Disease and Injury Incidence and Prevalence Collaborators
2016; GBD 2015 Risk Factors Collaborators 2016).
We estimated incidence and prevalence from the reco-
ded spectrum model. This model was updated with
assumptions of on-ART and off-ART mortality, as well as
other program data available from the UNAIDS country
files. Vital registration systems and sample registration
systems provide some of the most reliable sources for
estimation of HIV cause-specific deaths. Later, our cohort
incidence bias adjustment method was used to scale the
sizes of each incidence cohort on the basis of the raw
estimates of HIV mortality from spectrum, adjusted for
incompleteness and cause misclassification using unad-
justed incidence curves and those observed in the vital
registration system (Wang et al. 2016a). More details about
this method have been published previously (Wang et al.
2016b).
We also estimated risk factors following the GBD
study’s comparative assessment of risk factors detailed
elsewhere (Forouzanfar et al. 2015). Briefly, this method
uses data for excess mortality and disability associated with
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risk factors, data for exposure to risks, and evidence-based
assumptions on the desired counterfactual distribution of
risk exposure. The attributable burden of a risk factor is
estimated by multiplying DALYs from HIV/AIDS by the
population attributable fraction for HIV/AIDS due to that
risk factor.
We report age-standardized estimates, and 95% uncer-
tainty intervals (UI) for each estimate—such as rates or
numbers of deaths or DALYs. We estimated UIs by taking
1000 samples from the posterior distribution of each
quantity and using the 25th- and 975th-ordered draws of
the uncertainty distribution (Wang et al. 2016a). For 2015,
we estimated the expected burden for each of the three
measures (mortality, YLLs, and YLDs) as a function of
each country’s Socio-demographic Index (SDI)—a com-
posite measure based on levels of income—education, and
fertility (Wang et al. 2016a). SDI was developed for GBD
2015 to provide an interpretable synthesis of overall
development, as measured by lag-dependent income per
capita, average educational attainment in the population
over 15 years of age, and total fertility rates. In GBD 2015,
SDI was computed by rescaling each component to a scale
of zero to one, with zero being the lowest observed edu-
cational attainment, lowest income per capita, and highest
fertility rate from 1980 to 2015, and one being the highest
observed educational attainment, highest income per cap-
ita, and lowest fertility rate during that time, and then
taking the geometric mean of these values for each loca-
tion-year.
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.
Results
Mortality
The proportion of deaths attributable to HIV/AIDS has
increased steadily in the EMR since 1990 by 6.7% annually
(Fig. 1).
In 2015, HIV/AIDS caused 10,558 (95% UI
8411–17,775) deaths in the EMR, a tenfold increase from
1990 (936; 470–2226). This equals an increase in age-s-
tandardized rate from 0.3 (0.2–0.8) in 1990 to 1.8 (1.4–2.5)
per 100,000 population in 2015 (Table 1). HIV/AIDS
mortality among males—2.4 (1.8–3.4) deaths per 100,000
population—was double that among females—1.1
(0.9–1.5) deaths per 100,000 population. It affected mostly
infants and those aged 25 years or older (Fig. 2). HIV/
AIDS deaths as a percentage of all deaths decreased in
Kuwait, Lebanon and, Syria at an annualized rate of 3.3,
1.0, and 0.4%, respectively (Table 2). In 2015, the percent
of deaths due to HIV/AIDS was highest in Djibouti, and
higher than the regional average, 0.2 (0.1–0.2), in Bahrain,
Oman, Libya, Lebanon, Saudi Arabia Somalia, Sudan, and
UAE. It was lower than the regional average in all
remaining countries (Table 2).
Years of life lost
Years of life lost to HIV/AIDS increased from 49,094
(24,960–117,290) in 1990 to 526,030 (416,745–734,351) in
2015. The rate of YLLs increased as well for the same
period from 15.3 (7.6–36.2) to 81.8 (65.3–114.4) per
100,000 population (e-Table 1). E-Table 1 shows these
rates for individual countries. The percent of YLLs due to
HIV/AIDS decreased in Kuwait, Lebanon, Syria, and Qatar
at annualized rates of 3.4, 1.4, 0.3, and 0.1%, respectively
(Table 2).
Years lived with disability
HIV/AIDS accounted for 26,000 (16,440–38,839) YLDs in
2015, a sixfold increase from 3829 (1875–8539) in 1990.
The rate increased from 1.3 (0.6–3.1) per 100,000 popu-
lation in 1990 to 4.4 (2.7–6.6) in 2015 (e-Table 2).
E-Table 2 shows these rates for individual countries. The
percent of YLDs due to HIV/AIDS decreased in Lebanon,
Qatar, and Yemen by annualized rates of 2.2, 1.3, and
0.9%, respectively (Table 2).
HIV/AIDS caused more YLLs than YLDs at all times
(e-Fig. 1).
Disability-adjusted life years
DALYs due to HIV/AIDS increased tenfold between
1990—52,923 (26,913–124,169)—and 2015—552,030
(439,956–768,775). The rate increased from 16.6
(8.4–38.8) to 86.2 (69.2–120.6) per 100,000 population (e-
Table 3). E-Table 3 shows these rates for individual
countries. The percent of DALYs due to HIV/AIDS
decreased in Kuwait, Lebanon, Qatar, Syria, and Yemen by
annualized rates of 3.3, 1.5, 0.2, 0.2, and 0.1%, respectively
(Table 2).
Incidence and prevalence
Incidence and prevalence of HIV/AIDS have increased in
the EMR since 1990 from 2.9 (2.0–4.9) and 9.1 (5.1–16.4),
to 5.3 (3.9–7.9) and 28.4 (22.3–39.8) per 100,000 popula-
tion, respectively. The highest and lowest incidence for
2015 was observed in Djibouti and Syria, respectively: 90.9
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(55.0–142.4) and 0.4 (0.2–0.5). The highest and lowest
prevalence for 2015 were observed in Djibouti and Kuwait,
respectively: 919.7 (714.8–1161.9) and 0.0 (0.0–0.0) per
100,000 populations. Table 3 presents estimates of inci-
dence and prevalence of HIV/AIDS in EMR countries in
1990, 2005, and 2015.
Risk factors
Unsafe sex and drug use accounted for 74.1 and 18.8% of
HIV deaths, 75.3 and 17.5% of HIV YLLs, 71.9 and 21.3%
of HIV YLDs, and 75.1 and 17.7% of HIV DALYs,
respectively. In Djibouti, where HIV/AIDS mortality was
highest in comparison to all other EMR countries, unsafe
sex and drug use contributed to 94.4 and 0.4% of deaths
related to HIV/AIDS, respectively. On the other hand, in
Syria, where HIV/AIDS mortality was lowest, unsafe sex
and drug use contributed to 84.5 and 6.4% of deaths related
to HIV/AIDS, respectively. Table 4 presents estimates of
risk factors contribution to HIV/AIDS deaths, YLLs,
YLDs, and DALYs.
Observed versus expected burden
Despite the increase of HIV/AIDS mortality in EMR
countries over time, all, but Djibouti had lower observed
deaths than expected based on SDI (Table 1). Expected
deaths were within the range of uncertainty for the
observed deaths in Djibouti (Table 1). Only Djibouti had
higher observed YLLs and YLDs than what would have
been expected for 2015 based on SDI (e-Tables 1, 2).
Expected YLDs were within the range of uncertainty for
the observed YLDs in Bahrain, Lebanon, Libya, Saudi
Arabia, and the United Arab Emirates (e-Table 2).
Expected DALYs were within the range of uncertainty for
the observed DALYs in Djibouti and the United Arab
Emirates (e-Table 3).
Discussion
This is the first GBD study to comprehensively examine
the burden and trends of HIV/AIDS-related mortality in
EMR countries from 1990 to 2015. Our estimates show a
tenfold increase in HIV/AIDS mortality rates and other
measures of disease burden for the EMR region with most
of the HIV/AIDS burden is contributed by the three poorest
countries Djibouti, Somalia, and Sudan. These results
highlight the expanding nature of the epidemic in the EMR,
in contrast to the other global regions (UNAIDS 2016a).
They also affirm the epidemiological evidence indicating
emerging HIV epidemics within the last two decades such
as among MSM in nearly half of EMR countries (Mumtaz
et al. 2011, 2014a) and among PWID in over a third of
EMR countries (Mumtaz et al. 2014a, b), two populations
that are still being criminalized in this region, making
epidemic control harder to reach (Simmons 2014; Aaraj
and Chrouch 2016). Despite these rapid increases, HIV
disease burden in EMR remains at least tenfold lower than
HIV/AIDS mortality at the global level, and at all times
(Wang et al. 2016b).
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Table 1 Rates and 95% uncertainty levels (UL) of age-standardized HIV/AIDS mortality per 100,000 population in Eastern Mediterranean
Region countries observed in 1990, 2005, and 2015, and expected in 2015 based on Socio-demographic Index (SDI)
Location 1990 2005 2015
Rate (95% UL) Rate (95% UL) Observed rate (95% UL) Expected rate based
on SDI (SDI)
Eastern Mediterranean Region 0.3 (0.2–0.8) 1.5 (1.2–2.2) 1.8 (1.4–2.5) 35.1 (0.55)
Low and lower middle income
Afghanistan 0.5 (0.0–2.6) 1.1 (0.1–6.0) 1.0 (0.2–3.5) 45.0 (0.29)
Somalia 2.0 (0.7–4.4) 20.4 (13.4–28.3) 19.1 (13.8–25.0) 44.1 (0.15)
Djibouti 10.6 (2.7–30.0) 82.2 (53.7–115.9) 45.8 (30.8–60.9) 46.2 (0.46)
Egypt 0.0 (0.0–0.0) 0.2 (0.1–0.2) 0.2 (0.2–0.3) 31.2 (0.62)
Morocco 0.1 (0.1–0.1) 0.5 (0.4–0.6) 1.1 (0.8–1.4) 43.6 (0.50)
Pakistan 0.1 (0.0–0.5) 0.3 (0.0–1.7) 0.9 (0.2–3.2) 46.3 (0.47)
Palestine 0.0 (0.0–0.1) 0.3 (0.3–0.4) 0.4 (0.3–0.7) 35.9 (0.57)
Sudan 2.5 (0.7–5.5) 12.4 (8.6–16.6) 13.8 (10.5–16.4) 45.7 (0.43)
Syria 0.2 (0.2–0.2) 0.1 (0.1–0.1) 0.2 (0.1–0.3) 34.8 (0.58)
Tunisia 0.2 (0.0–0.1) 0.3 (0.2–0.3) 0.8 (0.6–1.0) 27.9 (0.65)
Yemen 0.8 (0.0–4.5) 1.5 (0.2–9.3) 0.8 (0.2–3.3) 45.5 (0.41)
Upper middle and high income
Iran 0.1 (0.0–0.1) 0.4 (0.4–0.5) 0.7 (0.5–1.0) 23.5 (0.72)
Iraq 0.0 (0.0–0.1) 0.2 (0.2–0.2) 0.4 (0.3–0.5) 34.8 (0.58)
Jordan 0.0 (0.0–0.1) 0.2 (0.1–0.2) 0.2 (0.1–0.3) 25.5 (0.70)
Lebanon 2.1 (0.1–17.1) 2.0 (0.2–12.7) 1.7 (0.3–8.2) 17.0 (0.75)
Libya 0.9 (0.0–5.0) 2.1 (0.0–12.9) 1.7 (0.1–9.0) 28.9 (0.64)
Bahrain 0.4 (0.1–0.8) 1.4 (1.0–2.0) 1.3 (0.8–2.2) 15.2 (0.78)
Kuwait 0.4 (0.3–0.4) 0.4 (0.4–0.5) 0.2 (0.2–0.2) 7.2 (0.86)
Oman 0.1 (0.1–0.1) 1.0 (0.9–1.3) 1.5 (1.1–2.0) 21.9 (0.73)
Qatar 0.3 (0.1–0.5) 0.5 (0.3–0.9) 0.3 (0.2–0.6) 12.4 (0.80)
Saudi Arabia 0.6 (0.1–3.1) 1.6 (0.6–5.6) 1.5 (0.7–4.0) 16.9 (0.76)
United Arab Emirates 1.0 (0.0–6.3) 2.6 (0.1–16.7) 2.2 (0.1–11.7) 7.2 (0.88)
Global Burden of Disease 2015 study, Eastern Mediterranean countries, 1990–2015
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These results indicate that EMR countries are not likely
to fulfill the Joint United Nations Program on HIV/AIDS
(UNAIDS) ‘‘90-90-90’’ target of diagnosing 90% of all
people living with HIV/AIDS, providing ART for 90% of
those diagnosed, and achieving viral suppression for 90%
of those treated, all by 2020 (UNAIDS 2014b). EMR
countries are also not likely to reach the fast-track target of
ending AIDS by 2030 (UNAIDS 2016a). The striking gap
between the expanding disease burden and global targets
for reducing this burden highlights the need for EMR
countries to strengthen HIV/AIDS voluntary counseling
and testing among the most at-risk populations, improve
HIV epidemiological surveillance, and scale up ART and
comprehensive prevention services.
A major challenge in the EMR is the weak vital regis-
tration and epidemiological surveillance systems. People
living with HIV are being diagnosed at a late stage of
disease progression, thus their chances of accessing treat-
ment and surviving are decreasing. Most HIV infections
appear to be detected through routine screening, such as in
the context of blood donation, premarital medical tests, and
employment, or visa and residency applications (Hermez
et al. 2010). Moreover, data on relevant HIV/AIDS indi-
cators, such as the Global AIDS Response Progress
Reporting indicators, are limited in many EMR countries,
although quality integrated bio-behavioral surveillance
surveys (IBBSS) of hard-to-reach populations have already
proven possible in over half of EMRO countries (Abu-
Raddad et al. 2010; Mumtaz et al. 2011, 2014b). Sustain-
ability of IBBSS rounds in countries where they have been
conducted, and implementing them in countries where they
have not been conducted, should be a priority.
These results also affirm the evidence indicating low
ART coverage in EMR and persistent challenges with the
treatment cascade (World Health Organization 2017;
UNAIDS 2016b). EMR has the lowest ART coverage
globally at a median of 17% in 2015 (UNAIDS 2016b), and
did not reach the 2015 midterm regional objective of 50%
Table 2 Percent of deaths, YLDs, and YLLs attributable to HIV/AIDS, and their relative annual percent change, 1990–2015, Eastern
Mediterranean Region countries
Location % Death Annual %
change
% YLLs Annual %
change
% YLDs Annual %
change
% DALYs Annual %
change
Eastern Mediterranean Region 0.2 (0.1–0.2) 6.7 0.3 (0.2–0.4) 6.7 0.0 (0.0–0.1) 4.7 0.2 (0.2–0.3) 6.6
Low and lower middle income
Afghanistan 0.0 (0.0–0.2) 2.7 0.1 (0.0–0.2) 2.5 0.0 (0.0–0.1) 1.4 0.1 (0.0–0.2) 2.4
Somalia 1.1 (0.5–1.9) 9.0 1.5 (0.7–2.6) 9.0 0.3 (0.2–0.6) 6.8 1.3 (0.7–2.0) 8.9
Djibouti 3.7 (2.1–5.5) 5.9 5.9 (3.6–8.8) 5.9 0.9 (0.6–1.4) 3.3 4.6 (3.0–6.6) 5.7
Egypt 0.0 (0.0–0.0) 7.7 0.1 (0.0–0.1) 7.7 0.0 (0.0–0.0) 7.4 0.0 (0.0–0.0) 7.7
Morocco 0.1 (0.1–0.2) 11.4 0.3 (0.2–0.4) 11.2 0.0 (0.0–0.1) 7.7 0.2 (0.1–0.2) 10.8
Pakistan 0.1 (0.0–0.3) 10.3 0.1 (0.0–0.4) 10.2 0.0 (0.0–0.1) 8.1 0.1 (0.0–0.3) 10.1
Palestine 0.1 (0.0–0.1) 9.3 0.1 (0.1–0.2) 9.2 0.0 (0.0–0.0) 8.8 0.1 (0.1–0.1) 9.2
Sudan 1.3 (0.9–1.7) 6.8 2.0 (1.4–2.7) 6.7 0.2 (0.1–0.4) 4.3 1.5 (1.1–1.9) 6.6
Syria 0.0 (0.0–0.0) -0.4 0.0 (0.0–0.1) -0.3 0.0 (0.0–0.0) 0.4 0.0 (0.0–0.0) -0.2
Tunisia 0.1 (0.1–0.2) 6.3 0.3 (0.2–0.4) 8.8 0.0 (0.0–0.0) 6.9 0.2 (0.1–0.2) 8.6
Yemen 0.1 (0.0–0.3) 0.1 0.1 (0.0–0.4) 0.0 0.0 (0.0–0.1) -0.9 0.1 (0.0–0.3) -0.1
Upper middle and high income
Iran 0.1 (0.1–0.1) 10.2 0.2 (0.1–0.2) 10.1 0.0 (0.0–0.0) 4.9 0.1 (0.1–0.2) 9.3
Iraq 0.0 (0.0–0.0) 10.1 0.1 (0.0–0.1) 10.1 0.0 (0.0–0.0) 9.8 0.0 (0.0–0.1) 10.1
Jordan 0.0 (0.0–0.1) 6.5 0.1 (0.0–0.1) 6.4 0.0 (0.0–0.0) 5.6 0.0 (0.0–0.1) 6.3
Lebanon 0.3 (0.0–1.4) -1.0 0.6 (0.1–2.7) -1.4 0.0 (0.0–0.1) -2.2 0.3 (0.1–1.4) -1.5
Libya 0.2 (0.0–1.1) 2.7 0.4 (0.0–2.2) 2.6 0.0 (0.0–0.2) 1.2 0.3 (0.0–1.4) 2.5
Bahrain 0.2 (0.1–0.4) 4.3 0.5 (0.3–0.9) 4.1 0.0 (0.0–0.1) 3.7 0.3 (0.2–0.4) 4.1
Kuwait 0.0 (0.0–0.0) -3.3 0.1 (0.1–0.1) -3.4 0.0 (0.0–0.0) 0.4 0.0 (0.0–0.1) -3.3
Oman 0.2 (0.2–0.3) 10.1 0.5 (0.3–0.6) 9.7 0.0 (0.0–0.1) 8.8 0.3 (0.2–0.4) 9.7
Qatar 0.1 (0.0–0.1) 0.3 0.1 (0.1–0.2) -0.1 0.0 (0.0–0.0) -1.3 0.1 (0.0–0.1) -0.2
Saudi Arabia 0.3 (0.1–0.7) 3.6 0.6 (0.3–1.6) 3.4 0.0 (0.0–0.1) 2.1 0.3 (0.2–0.9) 3.3
United Arab Emirates 0.3 (0.0–1.5) 3.3 0.6 (0.0–3.1) 3.2 0.0 (0.0–0.2) 1.2 0.4 (0.0–1.9) 3.0
Global Burden of Disease 2015 study, Eastern Mediterranean countries, 1990–2015
YLDs years lived with disability, YLLs years of life lost
S128 GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators
123
T
a
b
le
3
R
at
es
an
d
9
5
%
u
n
ce
rt
ai
n
ty
le
v
el
s
(U
L
)
o
f
ag
e-
st
an
d
ar
d
iz
ed
in
ci
d
en
ce
an
d
p
re
v
al
en
ce
o
f
H
IV
/A
ID
S
p
er
1
0
0
,0
0
0
p
o
p
u
la
ti
o
n
L
o
ca
ti
o
n
In
ci
d
en
ce
(9
5
%
U
L
)
P
re
v
al
en
ce
(9
5
%
U
L
)
1
9
9
0
2
0
0
5
2
0
1
5
1
9
9
0
2
0
0
5
2
0
1
5
E
as
te
rn
M
ed
it
er
ra
n
ea
n
R
eg
io
n
2
.9
(2
.0
–
4
.9
)
4
.7
(4
.0
–
5
.7
)
5
.3
(3
.9
–
7
.9
)
9
.1
(5
.1
–
1
6
.4
)
2
3
.4
(2
0
.0
–
2
8
.1
)
2
8
.4
(2
2
.3
–
3
9
.8
)
L
o
w
an
d
lo
w
er
m
id
d
le
in
co
m
e
A
fg
h
an
is
ta
n
2
.7
(0
.2
–
2
0
.5
)
1
.2
(0
.4
–
4
.2
)
2
.6
(0
.6
–
7
.3
)
1
0
.4
(0
.7
–
5
7
.8
)
9
.3
(1
.9
–
4
9
.0
)
1
4
.9
(4
.8
–
4
6
.7
)
S
o
m
al
ia
2
4
.7
(1
3
.1
–
4
5
.8
)
4
7
.4
(3
4
.8
–
6
2
.4
)
2
9
.2
(1
8
.7
–
4
5
.0
)
7
9
.5
(4
1
.1
–
1
4
3
.5
)
3
5
9
.2
(2
7
6
.3
–
4
6
6
.0
)
2
9
3
.1
(2
2
4
.8
–
3
8
0
.7
)
D
ji
b
o
u
ti
1
3
4
.5
(5
8
.4
–
2
8
1
.3
)
1
1
5
.8
(8
2
.6
–
1
5
9
.5
)
9
0
.9
(5
5
.0
–
1
4
2
.4
)
5
7
7
.6
(1
9
8
.5
–
1
5
0
1
.1
)
1
1
7
6
.9
(9
3
2
.3
–
1
4
7
2
.4
)
9
1
9
.7
(7
1
4
.8
–
1
1
6
1
.9
)
E
g
y
p
t
0
.3
(0
.2
–
0
.5
)
0
.5
(0
.4
–
0
.8
)
1
.2
(0
.7
–
1
.9
)
0
.0
(0
.0
–
0
.0
)
0
.5
(0
.1
–
1
.1
)
3
.1
(1
.6
–
4
.7
)
M
o
ro
cc
o
1
.6
(1
.3
–
1
.9
)
3
.9
(3
.2
–
5
.2
)
4
.7
(3
.9
–
5
.9
)
0
.0
(0
.0
–
0
.0
)
1
2
.3
(7
.6
–
1
7
.7
)
1
8
.6
(1
0
.2
–
2
9
.5
)
P
ak
is
ta
n
0
.9
(0
.4
–
4
.3
)
1
.8
(0
.9
–
4
.5
)
5
.6
(1
.9
–
1
5
.0
)
0
.7
(0
.0
–
4
.6
)
2
.6
(0
.4
–
9
.4
)
2
2
.3
(6
.0
–
5
9
.6
)
P
al
es
ti
n
e
0
.4
(0
.2
–
0
.6
)
1
.3
(0
.9
–
1
.9
)
2
.0
(1
.0
–
3
.4
)
0
.0
(0
.0
–
0
.0
)
3
.2
(1
.6
–
5
.1
)
7
.0
(3
.7
–
1
2
.0
)
S
u
d
an
1
5
.8
(6
.0
–
3
1
.2
)
2
9
.7
(2
2
.0
–
3
8
.5
)
1
5
.7
(7
.2
–
2
7
.5
)
7
9
.2
(2
5
.8
–
1
5
5
.2
)
1
9
7
.1
(1
5
5
.7
–
2
4
9
.7
)
1
6
7
.5
(1
3
1
.9
–
2
1
3
.6
)
S
y
ri
a
0
.2
(0
.2
–
0
.3
)
0
.2
(0
.1
–
0
.2
)
0
.4
(0
.2
–
0
.5
)
0
.0
(0
.0
–
0
.0
)
0
.0
(0
.0
–
0
.0
)
0
.6
(0
.1
–
1
.7
)
T
u
n
is
ia
0
.9
(0
.6
–
1
.3
)
1
.7
(1
.1
–
2
.6
)
3
.0
(1
.8
–
5
.0
)
0
.3
(0
.1
–
0
.7
)
6
.5
(3
.3
–
1
0
.5
)
1
6
.0
(7
.7
–
2
6
.9
)
Y
em
en
6
.4
(3
.4
–
3
1
.1
)
4
.4
(3
.3
–
8
.0
)
3
.7
(2
.1
–
7
.5
)
1
7
.3
(2
.1
–
9
7
.8
)
1
1
.9
(4
.0
–
4
1
.6
)
1
6
.8
(5
.0
–
4
1
.4
)
U
p
p
er
m
id
d
le
an
d
h
ig
h
in
co
m
e
Ir
an
2
.4
(2
.0
–
3
.3
)
5
.4
(4
.6
–
6
.3
)
6
.9
(5
.8
–
8
.2
)
0
.9
(0
.4
–
1
.5
)
9
.4
(6
.6
–
1
4
.4
)
1
1
.4
(7
.8
–
1
7
.8
)
Ir
aq
0
.2
(0
.1
–
0
.4
)
0
.7
(0
.5
–
1
.2
)
1
.6
(0
.4
–
3
.2
)
0
.0
(0
.0
–
0
.0
)
2
.0
(1
.0
–
3
.2
)
7
.6
(3
.8
–
1
3
.4
)
Jo
rd
an
0
.2
(0
.1
–
0
.4
)
0
.3
(0
.2
–
0
.5
)
0
.4
(0
.1
–
0
.8
)
0
.0
(0
.0
–
0
.0
)
0
.2
(0
.0
–
0
.5
)
0
.4
(0
.0
–
0
.9
)
L
eb
an
o
n
8
.8
(1
.6
–
6
2
.0
)
2
.4
(1
.0
–
7
.0
)
2
.7
(1
.0
–
6
.8
)
6
3
.0
(4
.3
–
4
4
7
.4
)
3
4
.6
(6
.3
–
1
7
5
.9
)
2
8
.6
(7
.0
–
1
2
3
.0
)
L
ib
y
a
6
.8
(2
.2
–
3
4
.0
)
5
.4
(2
.5
–
1
6
.5
)
5
.7
(2
.4
–
1
6
.1
)
2
6
.0
(0
.3
–
1
8
2
.8
)
2
4
.4
(1
.5
–
1
3
4
.4
)
2
9
.8
(2
.8
–
8
4
.1
)
B
ah
ra
in
2
.8
(1
.5
–
6
.2
)
3
.0
(2
.2
–
4
.3
)
4
.0
(1
.5
–
7
.6
)
9
.2
(0
.3
–
2
0
.1
)
2
1
.0
(9
.1
–
4
6
.2
)
2
8
.5
(1
2
.5
–
5
4
.1
)
K
u
w
ai
t
0
.9
(0
.5
–
1
.6
)
0
.4
(0
.3
–
0
.6
)
0
.4
(0
.1
–
0
.6
)
0
.4
(0
.0
–
1
.0
)
0
.0
(0
.0
–
0
.0
)
0
.0
(0
.0
–
0
.0
)
O
m
an
1
.0
(0
.7
–
1
.5
)
3
.5
(2
.6
–
4
.9
)
3
.1
(2
.2
–
4
.1
)
1
.4
(0
.6
–
2
.8
)
2
9
.3
(1
9
.3
–
4
3
.1
)
3
3
.7
(1
8
.3
–
5
0
.5
)
Q
at
ar
1
.1
(0
.4
–
3
.0
)
0
.3
(0
.2
–
0
.6
)
0
.4
(0
.1
–
0
.8
)
5
.5
(1
.3
–
9
.7
)
2
.5
(0
.8
–
4
.7
)
0
.9
(0
.2
–
1
.8
)
S
au
d
i
A
ra
b
ia
4
.0
(1
.4
–
1
7
.8
)
3
.3
(2
.1
–
6
.3
)
3
.8
(2
.2
–
6
.6
)
1
5
.2
(2
.5
–
8
0
.5
)
2
1
.1
(1
1
.0
–
4
8
.4
)
2
8
.2
(1
6
.4
–
5
1
.7
)
U
n
it
ed
A
ra
b
E
m
ir
at
es
6
.1
(0
.8
–
3
2
.3
)
4
.0
(0
.8
–
1
8
.4
)
4
.7
(0
.8
–
1
5
.7
)
1
1
.2
(0
.2
–
5
1
.8
)
2
6
.0
(1
.6
–
9
7
.2
)
3
6
.0
(3
.6
–
1
5
5
.5
)
G
lo
b
al
B
u
rd
en
o
f
D
is
ea
se
2
0
1
5
st
u
d
y
,
E
as
te
rn
M
ed
it
er
ra
n
ea
n
co
u
n
tr
ie
s,
1
9
9
0
–
2
0
1
5
Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015… S129
123
T
a
b
le
4
P
er
ce
n
t
an
d
9
5
%
u
n
ce
rt
ai
n
ty
le
v
el
s
(9
5
%
U
L
)
o
f
H
IV
/A
ID
S
d
ea
th
s,
Y
L
L
s,
Y
L
D
s,
an
d
D
A
L
Y
s
at
tr
ib
u
te
d
to
u
n
sa
fe
se
x
an
d
d
ru
g
u
se
L
o
ca
ti
o
n
P
er
ce
n
t
o
f
H
IV
/A
ID
S
d
ea
th
s
at
tr
ib
u
ta
b
le
to
P
er
ce
n
t
o
f
H
IV
/A
ID
S
Y
L
L
s
at
tr
ib
u
ta
b
le
to
P
er
ce
n
t
o
f
H
IV
/A
ID
S
Y
L
D
s
at
tr
ib
u
ta
b
le
to
P
er
ce
n
t
o
f
H
IV
/A
ID
S
D
A
L
Y
s
at
tr
ib
u
ta
b
le
to
U
n
sa
fe
se
x
(9
5
%
U
L
)
D
ru
g
u
se
(9
5
%
U
L
)
U
n
sa
fe
se
x
(9
5
%
U
L
)
D
ru
g
u
se
(9
5
%
U
L
)
U
n
sa
fe
se
x
(9
5
%
U
L
)
D
ru
g
u
se
(9
5
%
U
L
)
U
n
sa
fe
se
x
(9
5
%
U
L
)
D
ru
g
u
se
(9
5
%
U
L
)
E
as
te
rn
M
ed
it
er
ra
n
ea
n
R
eg
io
n
7
4
.1
(6
9
.1
–
7
9
.0
)
1
8
.8
(1
3
.6
–
2
4
.4
)
7
5
.3
(7
0
.7
–
7
9
.8
)
1
7
.5
(1
2
.6
–
2
2
.9
)
7
1
.9
(6
6
.9
–
7
6
.7
)
2
1
.3
(1
6
.3
–
2
7
.0
)
7
5
.1
(7
0
.5
–
7
9
.7
)
1
7
.7
(1
2
.8
–
2
3
.0
)
L
o
w
an
d
lo
w
er
m
id
d
le
in
co
m
e
A
fg
h
an
is
ta
n
7
4
.4
(6
6
.5
–
8
1
.1
)
1
6
.3
(9
.5
–
2
4
.5
)
7
4
.6
(6
7
.0
–
8
0
.9
)
1
5
.7
(9
.1
–
2
3
.6
)
7
4
.4
(6
6
.7
–
8
1
.2
)
1
6
.1
(9
.3
–
2
4
.3
)
7
4
.6
(6
7
.0
–
8
0
.9
)
1
5
.7
(9
.1
–
2
3
.6
)
S
o
m
al
ia
9
7
.3
(9
5
.8
–
9
8
.3
)
0
.9
(0
.5
–
1
.6
)
9
7
.4
(9
5
.8
–
9
8
.3
)
0
.9
(0
.5
–
1
.5
)
9
7
.3
(9
5
.8
–
9
8
.3
)
0
.9
(0
.5
–
1
.6
)
9
7
.4
(9
5
.8
–
9
8
.3
)
0
.9
(0
.5
–
1
.6
)
D
ji
b
o
u
ti
9
4
.4
(9
3
.1
–
9
5
.5
)
0
.4
(0
.3
–
0
.4
)
9
4
.2
(9
2
.8
–
9
5
.4
)
0
.3
(0
.3
–
0
.4
)
9
4
.4
(9
3
.3
–
9
5
.4
)
0
.4
(0
.3
–
0
.5
)
9
4
.2
(9
2
.8
–
9
5
.4
)
0
.3
(0
.3
–
0
.4
)
E
g
y
p
t
7
4
.2
(6
6
.5
–
8
0
.7
)
1
5
.8
(9
.0
–
2
3
.9
)
7
4
.4
(6
6
.8
–
8
0
.5
)
1
5
.0
(8
.7
–
2
3
.0
)
7
4
.2
(6
6
.4
–
8
0
.6
)
1
5
.7
(9
.0
–
2
3
.9
)
7
4
.4
(6
6
.9
–
8
0
.5
)
1
5
.1
(8
.7
–
2
3
.0
)
M
o
ro
cc
o
7
4
.0
(6
6
.1
–
8
0
.7
)
1
6
.1
(9
.2
–
2
4
.2
)
7
4
.2
(6
6
.6
–
8
0
.5
)
1
5
.6
(9
.0
–
2
3
.6
)
7
4
.0
(6
6
.3
–
8
0
.5
)
1
5
.9
(9
.1
–
2
4
.0
)
7
4
.2
(6
6
.6
–
8
0
.5
)
1
5
.6
(9
.0
–
2
3
.6
)
P
ak
is
ta
n
6
5
.9
(6
2
.5
–
6
9
.1
)
3
2
.6
(2
9
.3
–
3
6
.1
)
6
7
.5
(6
4
.3
–
7
0
.7
)
3
0
.9
(2
7
.7
–
3
4
.2
)
6
6
.2
(6
2
.9
–
6
9
.4
)
3
2
.3
(2
8
.9
–
3
5
.5
)
6
7
.3
(6
4
.2
–
7
0
.5
)
3
1
.0
(2
7
.8
–
3
4
.2
)
P
al
es
ti
n
e
7
4
.4
(6
6
.6
–
8
1
.1
)
1
6
.1
(9
.3
–
2
4
.3
)
7
4
.5
(6
7
.0
–
8
0
.9
)
1
5
.4
(9
.0
–
2
3
.5
)
7
4
.3
(6
6
.6
–
8
0
.8
)
1
5
.9
(9
.1
–
2
4
.0
)
7
4
.5
(6
6
.9
–
8
0
.9
)
1
5
.5
(9
.0
–
2
3
.5
)
S
u
d
an
7
4
.5
(6
6
.7
–
8
1
.2
)
1
6
.1
(9
.3
–
2
4
.2
)
7
4
.6
(6
6
.9
–
8
1
.1
)
1
5
.5
(9
.0
–
2
3
.6
)
7
4
.4
(6
6
.6
–
8
1
.1
)
1
6
.1
(9
.4
–
2
4
.4
)
7
4
.6
(6
6
.9
–
8
1
.1
)
1
5
.6
(9
.0
–
2
3
.7
)
S
y
ri
a
8
4
.5
(8
2
.1
–
8
6
.5
)
6
.4
(5
.5
–
7
.7
)
8
4
.5
(8
2
.0
–
8
6
.6
)
6
.1
(5
.2
–
7
.2
)
8
4
.5
(8
2
.2
–
8
6
.6
)
6
.3
(5
.4
–
7
.5
)
8
4
.5
(8
2
.0
–
8
6
.6
)
6
.1
(5
.2
–
7
.2
)
T
u
n
is
ia
7
7
.3
(7
4
.1
–
8
0
.0
)
1
5
.8
(1
3
.4
–
1
8
.4
)
7
7
.8
(7
4
.7
–
8
0
.5
)
1
5
.0
(1
2
.8
–
1
7
.4
)
7
8
.2
(7
5
.2
–
8
0
.9
)
1
4
.8
(1
2
.5
–
1
7
.3
)
7
7
.8
(7
4
.8
–
8
0
.5
)
1
5
.0
(1
2
.7
–
1
7
.4
)
Y
em
en
9
1
.0
(9
0
.0
–
9
2
.0
)
2
.9
(2
.5
–
3
.4
)
9
0
.8
(8
9
.7
–
9
1
.8
)
2
.8
(2
.4
–
3
.2
)
9
0
.6
(8
9
.5
–
9
1
.6
)
2
.9
(2
.5
–
3
.3
)
9
0
.8
(8
9
.7
–
9
1
.8
)
2
.8
(2
.4
–
3
.2
)
U
p
p
er
m
id
d
le
an
d
h
ig
h
in
co
m
e
Ir
an
1
4
.1
(1
2
.2
–
1
6
.2
)
7
8
.3
(7
5
.8
–
8
0
.8
)
1
4
.3
(1
2
.4
–
1
6
.5
)
7
7
.6
(7
5
.0
–
8
0
.3
)
1
4
.4
(1
2
.4
–
1
6
.7
)
7
7
.3
(7
4
.4
–
8
0
.0
)
1
4
.3
(1
2
.4
–
1
6
.5
)
7
7
.6
(7
5
.0
–
8
0
.2
)
Ir
aq
7
4
.4
(6
6
.7
–
8
0
.9
)
1
5
.9
(9
.2
–
2
3
.9
)
7
4
.5
(6
6
.9
–
8
0
.7
)
1
5
.2
(8
.8
–
2
3
.3
)
7
4
.3
(6
6
.8
–
8
0
.8
)
1
5
.8
(9
.1
–
2
3
.8
)
7
4
.5
(6
6
.8
–
8
0
.7
)
1
5
.3
(8
.9
–
2
3
.3
)
Jo
rd
an
8
1
.8
(7
9
.8
–
8
3
.6
)
9
.7
(8
.5
–
1
1
.2
)
8
1
.9
(7
9
.8
–
8
3
.7
)
9
.2
(8
.0
–
1
0
.5
)
8
1
.6
(7
9
.6
–
8
3
.5
)
9
.6
(8
.3
–
1
1
.0
)
8
1
.8
(7
9
.8
–
8
3
.7
)
9
.2
(8
.0
–
1
0
.6
)
L
eb
an
o
n
7
4
.2
(6
6
.0
–
8
1
.0
)
1
6
.5
(9
.7
–
2
4
.7
)
7
4
.3
(6
6
.6
–
8
0
.9
)
1
5
.9
(9
.3
–
2
3
.8
)
7
4
.3
(6
6
.3
–
8
1
.0
)
1
6
.3
(9
.4
–
2
4
.3
)
7
4
.3
(6
6
.6
–
8
0
.9
)
1
5
.9
(9
.3
–
2
3
.8
)
L
ib
y
a
7
4
.2
(6
6
.6
–
8
0
.7
)
1
5
.9
(9
.2
–
2
4
.0
)
7
4
.4
(6
6
.9
–
8
0
.5
)
1
5
.2
(8
.9
–
2
3
.2
)
7
4
.1
(6
6
.4
–
8
0
.6
)
1
5
.7
(9
.0
–
2
3
.9
)
7
4
.3
(6
6
.9
–
8
0
.5
)
1
5
.3
(8
.9
–
2
3
.2
)
B
ah
ra
in
3
6
.6
(3
3
.2
–
4
0
.3
)
5
7
.0
(5
3
.0
–
6
0
.5
)
3
7
.4
(3
3
.9
–
4
1
.0
)
5
5
.8
(5
2
.0
–
5
9
.4
)
3
7
.0
(3
3
.6
–
4
0
.8
)
5
6
.3
(5
2
.5
–
5
9
.9
)
3
7
.3
(3
3
.9
–
4
1
.0
)
5
5
.9
(5
2
.0
–
5
9
.4
)
K
u
w
ai
t
7
4
.3
(6
6
.8
–
8
0
.3
)
1
5
.3
(8
.9
–
2
3
.1
)
7
4
.7
(6
6
.4
–
8
0
.4
)
1
3
.4
(7
.4
–
2
2
.2
)
7
4
.2
(6
6
.5
–
8
0
.6
)
1
5
.9
(9
.1
–
2
4
.0
)
7
4
.7
(6
6
.5
–
8
0
.4
)
1
3
.5
(7
.5
–
2
2
.2
)
O
m
an
8
2
.8
(8
0
.2
–
8
5
.3
)
7
.6
(6
.2
–
8
.9
)
8
2
.7
(8
0
.1
–
8
5
.2
)
7
.3
(6
.0
–
8
.5
)
8
2
.4
(7
9
.8
–
8
4
.9
)
7
.5
(6
.2
–
8
.8
)
8
2
.6
(8
0
.1
–
8
5
.2
)
7
.3
(6
.1
–
8
.6
)
Q
at
ar
7
4
.6
(6
6
.6
–
8
1
.5
)
1
6
.6
(9
.6
–
2
5
.0
)
7
4
.8
(6
7
.1
–
8
1
.5
)
1
6
.0
(9
.2
–
2
4
.0
)
7
4
.6
(6
6
.9
–
8
1
.5
)
1
6
.3
(9
.4
–
2
4
.5
)
7
4
.7
(6
7
.1
–
8
1
.5
)
1
6
.0
(9
.2
–
2
4
.1
)
S
au
d
i
A
ra
b
ia
7
5
.0
(7
1
.4
–
7
8
.1
)
1
5
.5
(1
3
.1
–
1
8
.5
)
7
5
.2
(7
1
.6
–
7
8
.5
)
1
4
.8
(1
2
.5
–
1
7
.7
)
7
5
.0
(7
1
.5
–
7
8
.1
)
1
5
.3
(1
2
.9
–
1
8
.2
)
7
5
.2
(7
1
.6
–
7
8
.5
)
1
4
.9
(1
2
.5
–
1
7
.7
)
U
n
it
ed
A
ra
b
E
m
ir
at
es
7
4
.7
(6
6
.6
–
8
1
.6
)
1
6
.4
(9
.7
–
2
4
.9
)
7
4
.9
(6
7
.1
–
8
1
.2
)
1
5
.8
(9
.1
–
2
4
.1
)
7
4
.7
(6
7
.0
–
8
1
.5
)
1
6
.1
(9
.4
–
2
4
.3
)
7
4
.9
(6
7
.1
–
8
1
.2
)
1
5
.8
(9
.1
–
2
4
.1
)
G
lo
b
al
B
u
rd
en
o
f
D
is
ea
se
2
0
1
5
st
u
d
y
,
E
as
te
rn
M
ed
it
er
ra
n
ea
n
co
u
n
tr
ie
s,
1
9
9
0
–
2
0
1
5
Y
L
D
s
y
ea
rs
li
v
ed
w
it
h
d
is
ab
il
it
y
,
Y
L
L
s
y
ea
rs
o
f
li
fe
lo
st
,
D
A
L
Y
s
d
is
ab
il
it
y
-a
d
ju
st
ed
li
fe
y
ea
rs
S130 GBD 2015 Eastern Mediterranean Region HIV/AIDS Collaborators
123
coverage under the World Health Organization’s (WHO)
initiative to end EMR’s HIV treatment crisis (World Health
Organization Regional Office for the Eastern Mediter-
ranean 2014).
The effectiveness of highly active ART was manifested
in 1995 and became the new standard for HIV care in 1997,
making HIV a manageable disease (Carpenter et al. 1997;
Palmisano and Vella 2011). Despite this progress, only
three EMR countries showed a decrease in HIV/AIDS
mortality. These countries can share lessons with the
remaining EMR countries to help them control their epi-
demics. Moreover, our study showed that for most EMR
countries, the increase in YLLs exceeded by far the
increase in YLDs during the study period. For instance,
while YLDs contributed to 4.7% of HIV/AIDS DALYs in
EMR countries, they contributed to 8.4% in European
countries (Institute for Health Metrics and Evaluation
(IHME) 2017). This indicates that HIV survival is very low
in EMR countries, affirming the weak and challenged HIV/
AIDS response in this region (Abu-Raddad et al. 2013).
Even if HIV/AIDS treatment is available, often it is
interrupted and patients struggle to survive. Most health
care providers are also not well trained to manage HIV/
AIDS patients and/or understand their situations (Khosra-
vanifard et al. 2012; Wilder 2008; Anonymous 2012;
Thayer 2012; Upham and Mikkelsen 2012; Hedayati-
Moghaddam et al. 2012).
Interestingly, the observed burden of HIV/AIDS was
lower than expected in most EMR countries based on their
SDI. On the surface, this might be sound like good news.
However, the burden of HIV/AIDS has been increasing
continuously in the EMR despite the decrease in the rest of
the world. While SDI is known to be a strong indicator of
health outcomes (Wang et al. 2016a), it is possible that the
association with HIV/AIDS is modified by other cultural
and social factors in the EMR. SDI only deals with
socioeconomic inequalities between countries and does not
account for other cultural and social norms. For instance,
more of the risky behaviors for HIV, such as access to
drugs and alcohol, travel, or multiplicity of concurrent
relationships might be more common among higher-SDI
groups in the EMR. Further, some of the EMR countries
have experienced warfare and conflicts, highlighting the
difference in the social determinants of HIV in conflict
versus non-conflict settings, with HIV morbidity and
mortality closely associated with conflicts (Betsi et al.
2006; Mowafi 2011; Wirtz et al. 2014; Robertson and
Hoffman 2014; Doocy et al. 2015; Tunc¸alp et al. 2015;
Calam 2016). Some of these include sexual violence and
human rights abuses in conflict settings, interruption of
treatment due to mass displacement, disruption of health
systems, and resource diversions from health to support
wars. However, SDI allows comparisons between countries
based on similar indicators, and hence is important to use,
despite its limitations.
Meanwhile, the poor management and treatment of
HIV/AIDS patients is also a persistent issue. EMR poli-
cymakers need to devote adequate funds to expand HIV
prevention and treatment services even if the leading
causes of deaths, YLLs, and YLDs in the EMR are non-
communicable, such as ischemic heart disease, diabetes,
and road injuries (Mokdad et al. 2014, 2016). These ser-
vices need to be expanded, particularly among the most at-
risk populations. Countries need to put in place active
surveillance systems to detect early infections and monitor
the epidemic, in addition to delivering health care to those
affected. With drug use playing a significant role in HIV
transmission in this region, introducing syringe exchange
programs should be considered given its proven effec-
tiveness in preventing HIV transmission (Wilson et al.
2015).
Our study might be subjected to several limitations
around the estimation of HIV/AIDS burden. These limita-
tions have been previously described (Wang et al. 2016b).
In short, our study estimates mortality with HIV/AIDS as
the underlying cause of death without accounting for
deaths from other non-communicable causes among people
living with HIV. Additionally, data are less available for
the most recent years, and our models might have missed
recent progress, or lack of it, in some countries. Our esti-
mates have not accounted directly for relevant covariates
including prevalence of sexually transmitted infections or
rates of ART adherence, ART treatment failure, and HIV
testing (Wang et al. 2016b).
Our study showed that HIV/AIDS disease burden is
increasing in the vast majority of EMR countries, in con-
trast to the global declining trend. Increased and coordi-
nated efforts are needed in the region to apply lessons from
countries that have succeeded in controlling their epidemic
to reduce this burden, reverse its trend, and reach global
stipulated targets for HIV/AIDS. More affluent EMR
countries must consider ways to bring the region’s more
disadvantaged countries to the same level of health. These
findings highlight the need for EMR countries to strengthen
HIV/AIDS voluntary counseling and testing among the
most at-risk populations, improve HIV epidemiological
surveillance, and scale up ART and comprehensive pre-
vention services.
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